Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 338

Results For "CE"

9352 News Found

Alembic Pharmaceuticals receives USFDA approval for Lacosamide tablets
Drug Approval | March 21, 2022

Alembic Pharmaceuticals receives USFDA approval for Lacosamide tablets

The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older


Akston Biosciences and Biolexis partner to develop second-gen COVID-19 vaccine
News | March 19, 2022

Akston Biosciences and Biolexis partner to develop second-gen COVID-19 vaccine

Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships


Jubilant Pharmova arm receives ANDA approval for psychoneurosis drug
Drug Approval | March 19, 2022

Jubilant Pharmova arm receives ANDA approval for psychoneurosis drug

The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis


Merck discontinues KEYLYNK-101 trial to treat prostate cancer
Biotech | March 18, 2022

Merck discontinues KEYLYNK-101 trial to treat prostate cancer

At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide


Flipkart Health+ appoints Prashant Jhaveri as CEO
People | March 17, 2022

Flipkart Health+ appoints Prashant Jhaveri as CEO

Prashant comes with over 17 years of experience in the health, health insurance and other allied healthcare sectors


Roche introduces molecular testing solutions to differentiate Covid-19 variants
Medical Device | March 17, 2022

Roche introduces molecular testing solutions to differentiate Covid-19 variants

Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta


Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with breast cancer
Drug Approval | March 17, 2022

Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with breast cancer

First PARP inhibitor to demonstrate overall survival benefit in early breast cancer


Agilent establishes Centre for Excellence at Gujarat Technological University
Medical Device | March 17, 2022

Agilent establishes Centre for Excellence at Gujarat Technological University

The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences


Beghou Consulting strengthens advanced analytics and data science team in Pune
News | March 17, 2022

Beghou Consulting strengthens advanced analytics and data science team in Pune

Since 1993, Beghou Consulting has helped life sciences companies - especially emerging pharmaceutical companies - establish and manage commercial operations to better market and sell therapies


USFDA approves Rinvoq for ulcerative colitis
Drug Approval | March 17, 2022

USFDA approves Rinvoq for ulcerative colitis

First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology